Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA sunscreen TFM proposed amendment on UVA testing methods, labeling upcoming.

This article was originally published in The Tan Sheet

Executive Summary

AVOBENZONE SUNSCREEN INTERIM MARKETING APPROVAL DUE BY END OF MARCH, FDA's John Lipnicki, an interdisciplinary scientist in the Division of OTC Drug Products, said at a sunscreen OTC "feedback" meeting with the Cosmetic, Toiletry & Fragrance Association and the Nonprescription Drug Manufacturers Association Feb. 11 in Rockville, Md. While "an estimate...on the completion time" for the final rule on OTC sunscreens is not available, FDA plans on "making a determination as soon as possible on the interim marketing status of avobenzone," Lipnicki said.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086690

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel